Ruth Etzioni
#134,810
Most Influential Person Now
American biostatistician
Ruth Etzioni's AcademicInfluence.com Rankings
Ruth Etzionimathematics Degrees
Mathematics
#7144
World Rank
#9771
Historical Rank
Statistics
#791
World Rank
#879
Historical Rank
Download Badge
Mathematics
Ruth Etzioni's Degrees
- PhD Biostatistics University of Washington
- Masters Biostatistics University of Washington
- Bachelors Mathematics University of California, Berkeley
Similar Degrees You Can Earn
Why Is Ruth Etzioni Influential?
(Suggest an Edit or Addition)According to Wikipedia, Ruth D. Etzioni is a biostatistician who develops statistical computer models to research cancer progression. She is the Rosalie and Harold Rea Brown endowed chair at the Fred Hutchinson Cancer Research Center.
Ruth Etzioni's Published Works
Published Works
- Phases of biomarker development for early detection of cancer. (2001) (1509)
- Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. (2015) (1092)
- Early detection of prostate cancer: AUA Guideline. (2013) (1061)
- Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society (2018) (1049)
- American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 (2010) (829)
- Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. (2009) (749)
- Overdiagnosis and overtreatment of prostate cancer. (2014) (728)
- Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. (2002) (711)
- Early detection: The case for early detection (2003) (703)
- American Cancer Society lung cancer screening guidelines (2013) (638)
- Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data (2002) (469)
- Estimating medical costs from incomplete follow-up data. (1997) (455)
- Quantifying the role of PSA screening in the US prostate cancer mortality decline (2008) (391)
- Quality of life in survivors of colorectal carcinoma (2000) (342)
- Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer (2016) (326)
- Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States (2017) (325)
- Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society (2020) (304)
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer (2016) (255)
- Prostate cancer early detection. Clinical practice guidelines in oncology. (2010) (226)
- Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. (1999) (223)
- Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. (2003) (217)
- NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. (2016) (215)
- Prostate cancer early detection, Version 2.2016: Featured updates to the NCCN guidelines (2016) (206)
- Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. (1999) (193)
- Comparison of survival outcomes among cancer patients treated in and out of clinical trials. (2014) (185)
- Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society (2016) (173)
- Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials (2017) (159)
- Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. (2004) (158)
- NCCN clinical practice guidelines in oncology: prostate cancer early detection. (2010) (152)
- Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies (2013) (149)
- Combining Results of Microarray Experiments: A Rank Aggregation Approach (2006) (134)
- Cost-Effectiveness of Microsatellite Instability Screening as a Method for Detecting Hereditary Nonpolyposis Colorectal Cancer (2001) (133)
- Influence of Study Features and Methods on Overdiagnosis Estimates in Breast and Prostate Cancer Screening (2013) (131)
- Asymptomatic incidence and duration of prostate cancer. (1998) (130)
- Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase (2006) (125)
- Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends (2008) (124)
- On the use of survival analysis techniques to estimate medical care costs. (1999) (124)
- Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. (2014) (117)
- Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. (2003) (115)
- Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. (2002) (113)
- Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. (2005) (108)
- Incorporating the Time Dimension in Receiver Operating Characteristic Curves: A Case Study of Prostate Cancer (1999) (106)
- The prostate cancer conundrum revisited (2012) (104)
- National trends in the management of low and intermediate risk prostate cancer in the United States. (2015) (104)
- Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach (2008) (101)
- Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. (2004) (99)
- Estimating the costs attributable to a disease with application to ovarian cancer. (1996) (97)
- Combining biomarkers to detect disease with application to prostate cancer. (2003) (93)
- Is prostate cancer different in black men? Answers from 3 natural history models (2017) (86)
- Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. (2014) (85)
- Expected population impacts of discontinued prostate‐specific antigen screening (2014) (84)
- Metastases of prostate cancer express estrogen receptor-beta. (2004) (84)
- Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey (2007) (84)
- Androgen receptor polymorphisms and the incidence of prostate cancer. (2002) (78)
- Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. (1997) (76)
- Prostate cancer early detection version 1 (2014) (75)
- Loss of stearoyl‐CoA desaturase expression is a frequent event in prostate carcinoma (2005) (72)
- Basic Statistical Methods (2006) (70)
- The impact of PLCO control arm contamination on perceived PSA screening efficacy (2012) (69)
- Limitations of Basing Screening Policies on Screening Trials: The US Preventive Services Task Force and Prostate Cancer Screening (2013) (68)
- Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2015) (68)
- The effectiveness of mammography promotion by volunteers in rural communities. (2000) (67)
- Association of Insurance and Race/Ethnicity with Disease Severity among Men Diagnosed with Prostate Cancer, National Cancer Database 2004-2006 (2010) (66)
- Optimal Experimental Design for Another's Analysis (1993) (65)
- Cancer Outcomes in DCIS Patients Without Locoregional Treatment. (2019) (64)
- Bayesian statistical methods in public health and medicine. (1995) (63)
- Influence of publication of US and European prostate cancer screening trials on PSA testing practices. (2011) (63)
- Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. (2010) (62)
- Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy (2012) (62)
- Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. (2005) (60)
- Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. (1999) (59)
- Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. (2016) (58)
- Depression and incident lower limb amputations in veterans with diabetes. (2011) (58)
- What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models (2011) (57)
- The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials (2018) (55)
- Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. (2007) (55)
- Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. (2015) (55)
- Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer (2002) (53)
- AUDIT-C alcohol screening results and postoperative inpatient health care use. (2012) (53)
- Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. (2010) (53)
- Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. (2011) (52)
- Marrow transplantation from unrelated volunteer donors. (1995) (51)
- Prostate Cancer Early Detection, Version 2.2015 (2015) (50)
- Prospective quality‐of‐life outcomes for low‐risk prostate cancer: Active surveillance versus radical prostatectomy (2015) (49)
- Trends in Treatment Costs for Localized Prostate Cancer: The Healthy Screenee Effect (2007) (49)
- The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. (2001) (49)
- Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. (2018) (49)
- Community organization to promote breast cancer screening among women ages 50-75. (1995) (48)
- Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. (2006) (46)
- A reality check for overdiagnosis estimates associated with breast cancer screening. (2014) (46)
- Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population‐based mammographic screening (2017) (45)
- Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial (2014) (44)
- Individualized estimates of overdiagnosis in screen-detected prostate cancer. (2014) (43)
- The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing (2004) (43)
- Modeling grade progression in an active surveillance study (2014) (42)
- Is prostate cancer screening cost‐effective? A microsimulation model of prostate‐specific antigen‐based screening for British Columbia, Canada (2014) (42)
- Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? (2004) (41)
- An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. (2004) (41)
- Combining longitudinal studies of PSA. (2004) (39)
- IGF‐I and IGFBP‐3 polymorphisms and risk of prostate cancer (2005) (37)
- Cluster-based network model for time-course gene expression data. (2007) (37)
- Measuring Costs: Administrative Claims Data, Clinical Trials, and Beyond (2002) (36)
- The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model (2016) (36)
- Models in the Development of Clinical Practice Guidelines (2014) (35)
- Simulation modeling of outcomes and cost effectiveness. (2000) (35)
- Reconsidering the Trade-offs of Prostate Cancer Screening. (2020) (34)
- Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. (2018) (34)
- Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts (2018) (34)
- Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms (2016) (33)
- Design and analysis of cancer screening trials (1995) (33)
- Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States (2009) (32)
- Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. (2015) (32)
- NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. (2015) (31)
- Polymorphic markers in the 5α‐reductase type II gene and the incidence of prostate cancer (2003) (31)
- Studies of prostate-cancer mortality: caution advised. (2008) (30)
- Analysis of case-control studies of screening: impact of misspecifying the duration of detectable preclinical pathologic changes. (1998) (29)
- Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context. (2016) (28)
- Increasing Use of Radical Prostatectomy for Nonlethal Prostate Cancer in Sweden (2012) (28)
- Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. (1998) (27)
- Age‐specific prostate‐specific antigen: A reassessment (1996) (26)
- Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. (2014) (25)
- Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. (2013) (24)
- It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. (2008) (24)
- Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer (2018) (23)
- Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort (2022) (22)
- Modeling Disease Progression With Longitudinal Markers (2008) (22)
- Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. (2016) (22)
- The diffusion of docetaxel in patients with metastatic prostate cancer. (2015) (21)
- Estimating asymptomatic duration in cancer: the AIDS connection. (1997) (21)
- Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer (2007) (21)
- Estimating the Influence of Rescreening Interval on the Benefits Associated with Cancer Screening: Approaches and Limitations (2002) (20)
- Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis (2003) (20)
- What Happens After an Elevated PSA Test: The Experience of 13,591 Veterans (2010) (20)
- Methods for Assessing Improvement in Specificity When a Biomarker is Combined With a Standard Screening Test (2009) (19)
- On the catch-up time method for analyzing cancer screening trials. (1995) (19)
- Statistical methods for analyzing speedup learning experiments (2004) (19)
- Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer (2015) (19)
- Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics (2014) (18)
- Accounting for uncertainty during a pandemic (2020) (18)
- Tumor marker usage and medical care costs among older early-stage breast cancer survivors. (2015) (17)
- Case-Control Studies of the Efficacy of Cancer Screening: Overcoming Bias From Nonrandom Patterns of Screening (2004) (17)
- Differential Expression and Network Inferences through Functional Data Modeling (2009) (17)
- Building Better Models (2012) (17)
- Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. (2013) (16)
- Analyzing Patterns of Staining in Immunohistochemical Studies: Application to a Study of Prostate Cancer Recurrence (2005) (16)
- Monitoring of a pilot toxicity study with two adverse outcomes. (1994) (16)
- Estimated impact of the prostate cancer prevention trial on population mortality (2005) (15)
- Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: matching for transplants from related haploidentical donors. (1994) (14)
- Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials (2018) (14)
- The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. (2021) (14)
- Optimizing Sampling Strategies for Estimating Quality-adjusted Life Years (1997) (14)
- What do the screening trials really tell us and where do we go from here? (2014) (14)
- Oversimplifying Overdiagnosis (2014) (13)
- Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. (2022) (12)
- Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer (2020) (12)
- Multi-Cancer Early Detection: Learning from the past to Meet the Future. (2021) (12)
- Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence. (2013) (11)
- Missteps in Current Estimates of Cancer Overdiagnosis. (2017) (11)
- Biopsy follow-up of prostate-specific antigen tests. (2012) (11)
- A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data (2018) (11)
- A likelihood ratio test for cancer screening trials. (1995) (11)
- Letters to the Editor/Errata Re: Early Detection of Prostate Cancer: AUA guideline (2013) (11)
- Effect of Screening Mammography on Cancer Incidence and Mortality. (2015) (10)
- Models in the development of clinical practice guidelines. (2015) (10)
- Racial disparities in prostate cancer survival in a screened population: Reality versus artifact (2018) (10)
- Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. (2011) (9)
- A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden. (2017) (9)
- Lifetime benefits and harms of PSA-based risk screening for prostate cancer. (2020) (9)
- Can Administrative Data Identify Incident Cases of Colorectal Cancer? A Comparison of Two Health Plans (2004) (9)
- Statistical issues in the evaluation of screening and early detection modalities. (2008) (9)
- Overdiagnosis and lives saved due to reflex testing men with intermediate prostate-specific antigen levels. (2019) (9)
- Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society (vol 314, pg 1599, 2015) (2016) (8)
- Community attitudes and mammography use: does it really matter what other people think? (1999) (8)
- ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. (2018) (8)
- Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. (2007) (8)
- Endogenous Sex Hormones and Prostate Cancer Risk (2003) (8)
- Much ado about mammography variability. (2002) (8)
- Proportion of biochemically-recurrent prostate cancer patients with durable undetectable PSA after short-course androgen deprivation therapy. (2018) (7)
- Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. (2013) (7)
- Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. (2021) (7)
- Statistical models for the analysis of ordered categorical data in public health and medical research (1994) (7)
- Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer (2021) (7)
- Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer (2020) (7)
- Statistical Methods for Analyzing Speedup Learning Experiments (1994) (7)
- Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage. (2020) (6)
- Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study. (2021) (6)
- A Framework for Treatment Decision Making at Prostate Cancer Recurrence (2016) (6)
- Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication. (2019) (6)
- Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts (2020) (6)
- Modelling the effect of screening for cervical cancer on the population (2004) (6)
- Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development (2012) (5)
- Treatment Trends for Stage I Testicular Seminoma in an Equal-Access Medical System. (2016) (5)
- Modeling the Effect of a Preventive Intervention on the Natural History of Cancer: Application to the Prostate Cancer Prevention Trial (2006) (5)
- Beyond classic risk adjustment: Socioeconomic status and hospital performance in urologic oncology surgery (2018) (5)
- Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? (2013) (5)
- Measures of survival benefit in cancer drug development and their limitations. (2015) (5)
- Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials (2018) (5)
- Estimating the frequency of indolent breast cancer in screening trials (2019) (5)
- PD30-10 DEFINITIVE AND SUSTAINED INCREASE IN PROSTATE CANCER METASTASES IN THE UNITED STATES (2019) (5)
- Overview of US Prostate Cancer Trends in the Era of PSA Screening (2009) (5)
- Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer (2016) (4)
- The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations (2018) (4)
- Comparative Effectiveness of Biomarkers to Target Cancer Treatment (2016) (4)
- A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing (2021) (4)
- Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study (2020) (4)
- Prostate cancer and computer models: Background, limitations, and potential. (1996) (4)
- Impact of novel systemic therapies on the first‐year costs of care for melanoma among Medicare beneficiaries (2021) (4)
- Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort. (2013) (4)
- Breast Cancer Screening forWomen at Average Risk 2015 Guideline Update From the American Cancer Society (2015) (3)
- A Latent Disease Model to Reduce Detection Bias in Cancer Risk Prediction Studies (2021) (2)
- Identifying breast cancer recurrence histories via patient-reported outcomes (2021) (2)
- The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge (2022) (2)
- Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach (2020) (2)
- Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality (2017) (2)
- Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas (2022) (1)
- Predictors of preoperative MRI for breast cancer: differences by data source. (2015) (1)
- MP78-11 ONGOING GLEASON GRADE MIGRATION IN LOCALIZED PROSTATE CANCER AND IMPLICATIONS FOR USE OF ACTIVE SURVEILLANCE (2004-2010) (2014) (1)
- Bayesian Analysis of the Ames Salmonella /Microsome Assay (1993) (1)
- American Urological Association ( AUA ) Guideline EARLY DETECTION OF PROSTATE CANCER : AUA GUIDELINE (2018) (1)
- Prostate Cancer Early Detection Panel Members (2015) (1)
- Estimating the Number of Men Living with Metastatic Prostate Cancer in the United States. (2023) (1)
- When to Discuss Prostate Cancer Screening With Average-Risk Men. (2021) (1)
- NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. (2023) (1)
- SERIAL PSA SCREENING FOR PROSTATE CANCER: A COMPUTER MODEL EVALUATES COMPETING STRATEGIES (1999) (1)
- Associations of Obesity with Prostate Cancer Risk Differ Between U.S. African-American and Non-Hispanic White Men: Results from the Selenium and Vitamin E Cancer Prevention Trial (2015) (1)
- Duration of the first off treatment period is associated with time to androgen independence (AI) and survival in men with localized or biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation (IAD) (2007) (1)
- Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). (2012) (1)
- RE: A model too far. (2014) (1)
- Erratum: On the catch-up time method for analyzing cancer screening trials (Biometrics (March 1995) 51 (31-43)) (1995) (1)
- Alternative Prostate Cancer Screening Strategies (2013) (1)
- Using Public Health Data to Evaluate Screening Programs (2009) (1)
- Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy. (2021) (0)
- P0: Progress to zero: A simple metric to measure COVID-19 progress by country/region (2020) (0)
- FOLLOW UP AND BIOPSY PATTERNS AFTER ELEVATED PROSTATE SPECIFIC ANTIGEN (PSA) TESTS (2009) (0)
- LBA02-08 RECONSIDERING THE TRADEOFFS OF PROSTATE CANCER SCREENING (2020) (0)
- 311 COSTS AND SEQUELA FOLLOWING PSA TESTING AMONG HEALTHY INSURED MEN IN THE U.S. (2011) (0)
- Treatment and survival of de novo metastatic prostate cancer in US veterans. (2023) (0)
- Regression Analysis (2020) (0)
- Mathematical Issues: PSA Testing (2001) (0)
- Reply by Authors. (2019) (0)
- Testosterone kinetics in the first cycle of intermittent androgen deprivation (IAD) for men with localized or biochemical relapse (BR) of prostate cancer (PC) (2008) (0)
- Networks Discovery through Timing Maps (2007) (0)
- PCN166 Comparative Effectiveness and Cost-Effectiveness of Reflex Testing Men with Intermediate PSA Levels: A Systematic Model-Based Analysis (2021) (0)
- PS2-43: Prostate-Specific Antigen Tests in Clinical Practice over the Past Decade: Is the Threshold for Recommending Biopsy Dropping? (2011) (0)
- Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence. (2010) (0)
- Key Statistical Concepts (2020) (0)
- Abstract IA018: Opportunity for interception as a driver of benefit in cancer early detection: implications for multi-cancer early detection testing (2023) (0)
- 1988 DECLINES IN PSA UTILIZATION AFTER THE 2008 PSA SCREENING GUIDELINES (2010) (0)
- 1 Accounting for Uncertainty During a Pandemic 1 (2021) (0)
- OP-JNCI210168 1..4 (2021) (0)
- SERIAL PROSTATE SPECIFIC ANTIGEN (PSA) AND FREE/TOTAL PSA (F/T PSA) RATIO IN THE DIAGNOSIS OF PROSTATE CANCER (1999) (0)
- PD34-10 TRENDS IN MANAGEMENT OF LOW-RISK PROSTATE CANCER IN THE UNITED STATES: A POPULATION-BASED ANALYSIS (2014) (0)
- Predictors of Preoperative Magnetic Resonance Imaging for Breast Cancer: Differences by Data Source (2018) (0)
- Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. (2019) (0)
- Abstract A09: Predicting recurrence or second breast cancer using linked claims and cancer registry data with limited gold-standard information: A gradient-boosting approach (2020) (0)
- Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance. (2015) (0)
- Abstract FO01-01: Estimating how many prostate cancers are overdiagnosed: Overcoming challenges and avoiding mistakes (2012) (0)
- Survey Data Analysis (2020) (0)
- Projecting Bene fi ts and Harms of Novel Cancer Screening Biomarkers : A Study of PCA 3 and Prostate Cancer (2015) (0)
- Count Outcomes (2020) (0)
- Concurrent with increasing prostate cancer incidence and declining prostate cancer mortality in the US , the prevalence of obesity (2009) (0)
- Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multi-Cancer Early Detection Tests. (2022) (0)
- Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer (2023) (0)
- Statistical Methods Experiments for Analyzing Speedup Learning (1994) (0)
- Active Surveillance for Ductal Carcinoma in Situ: Shining Light Into the Modeling Abyss. (2016) (0)
- Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study (Preprint) (2020) (0)
- HEALTH SYSTEM STRUCTURE AND READMISSIONS AFTER UROLOGIC CANCER SURGERY: PD14‐07 (2017) (0)
- Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort (2022) (0)
- Bootstrap Methods (2020) (0)
- Refl ection and Reaction (0)
- Binary and Categorical Outcomes (2020) (0)
- Abstract P4-03-03: Elevated Risk of Breast Cancer Diagnosis in Women with Dense Breasts reflects a similarly Elevated Risk of Breast Cancer Onset that is Robust to the Effect of Density on Mammography Sensitivity (2023) (0)
- Bayesian group sequential sampling with application to tax auditing (1990) (0)
- Undetectable prostate‐specific antigen after short‐course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis‐free survival and prostate cancer‐specific survival (2018) (0)
- Cost-effectiveness and lifetime implications of using finasteride to reduce prostate cancer incidence and mortality. (2004) (0)
- Abstract GS4-06: Estimation of breast cancer overdiagnosis in a US breast screening cohort (2022) (0)
- Association of undetectable PSA with time to metastasis and survival after short-course androgen deprivation therapy for biochemically-recurrent prostate cancer patients. (2018) (0)
- Overview Prostate cancer is the most commonly diagnosed The NCCN Prostate Cancer Early Detection Clinical Practice Guidelines in OncologyTM (2010) (0)
- Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective. (2020) (0)
- Spatial prediction of COVID-19 pandemic dynamics in the United States (2022) (0)
- Abstract PO-211: Racial disparities in the quality of surgical care among Medicare beneficiaries with prostate cancer (2020) (0)
- Case-control studies of cancer surveillance procedures. (2011) (0)
- Prediction (2020) (0)
- Cancer Modeling as Learning Experience. (2022) (0)
- Abstract 23: Will novel systemic treatments alter the benefit of lung cancer screening?: A microsimulation study (2022) (0)
- Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study (Preprint) (2020) (0)
- Abstract B100: The role of place in racial disparities in prostate cancer treatment (2023) (0)
- Causal Inference (2022) (0)
- Corrigendum to definitive and sustained increase in prostate cancer metastases in the United States. (2022) (0)
- Flying Blind on the Origin of the Pandemic (2021) (0)
- Beyond classical risk adjustment: Socioeconomic status and hospital performance in urologic oncology. (2017) (0)
- Title: Spatial prediction of COVID-19 pandemic dynamics in the United States Brief Title: Spatial modeling of COVID-19 in the US (2022) (0)
- Medical Decision Making Reviewers, 2013 (2014) (0)
- Abstract 5242: Obtaining a transcriptomic profile of a single prostate cancer cell (2011) (0)
- The Coronavirus Will Be With Us For Years to Come (2020) (0)
- Time to testosterone (T) and PSA rises during first “off treatment” interval (1OFF-2ON) of intermittent androgen deprivation (IAD) as prognostic for time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). (2012) (0)
- Impact of prostate-specific antigen screening: building confidence. (2014) (0)
- 190 Oregon’s War On MelanomaTM: A statewide public health experiment (2019) (0)
- Benchmarking COVID-19 Mortality in the United States (2020) (0)
- Statistics and Health Data (2020) (0)
- Impact of cancer screening on metastasis: A prostate cancer case study (2021) (0)
- Shopping for New Cancer Screening Tests. (2023) (0)
- PCN7 TRENDS IN CHEMOTHERAPY USE, OUTCOMES, AND COST FOR PATIENTS WITH ADVANCED NONSMALL LUNG CANCER: EVIDENCE FROM SEER-MEDICARE (2004) (0)
- Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). (2012) (0)
- When Clinical Trials Disagree (2018) (0)
- Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis (2022) (0)
- Survival trends in de novo metastatic prostate cancer: SEER and Veterans Affairs comparison. (2023) (0)
- Estimating stage-specific sensitivity for cancer screening tests (2023) (0)
- Statistics for Health Data Science (2020) (0)
- Projecting the impact of treatment advances on the mortality results of mammography screening trials. (2015) (0)
- Health Care Costs (2020) (0)
- single-center study disease after marrow transplantation from HLA-matched siblings: a methylprednisolone for the prevention of acute graft-versus-host Tacrolimus (FK506) alone or in combination with methotrexate or (2011) (0)
- The impact of PLCO control arm contamination on perceived PSA screening efficacy (2012) (0)
- PCN175 Pan-Cancer Early Detection Tests: Considering Potential Benefits and Harms (2021) (0)
- Modeling the impact of novel systemic treatments on lung cancer screening benefits (2022) (0)
- Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study (2020) (0)
This paper list is powered by the following services:
Other Resources About Ruth Etzioni
What Schools Are Affiliated With Ruth Etzioni?
Ruth Etzioni is affiliated with the following schools: